Table 1

Summary of clinical trials involving PD-1 and LAG-3 single or combination immune checkpoint inhibitor treatment

ClinicalTrials.gov IDDrug nameTargetConditionsPhaseEnrollment (Actual)SponsorStudy Start
NCT03679767RetifanlimabPD-1Metastatic non-small cell lung Cancer, locally advanced urothelial cancer, metastatic urothelial cancer, unresectable melanoma, metastatic melanoma, locally advanced renal cell carcinoma, metastatic clear-cell renal cell carcinomaPhase 2121Incyte Corporation2019-01-09
NCT01295827PembrolizumabPD-1Locally advanced or metastatic carcinoma, melanoma, non-small cell lung carcinomaPhase 11260Merck Sharp & Dohme LLC2011-03-04
NCT05802290NivolumabPD-1Squamous cell carcinoma of head and neckPhase 3124Gruppo Oncologico del Nord-Ovest2017-11-27
NCT00730639NivolumabPD-1Metastatic castration-resistant prostate cancer, renal cell carcinoma, metastatic melanoma, non-small cell lung cancerPhase 1395Bristol-Myers Squibb2008-10-30
NCT02061761RelatlimabLAG-3Hematologic neoplasmsPhase 1-Phase 2106Bristol-Myers Squibb2014-03-13
NCT03489369Sym022LAG-3Metastatic cancer, solid tumor, lymphomaPhase 115Symphogen A/S2018-05-08
RELATIVITY-047/NCT03470922Relatlimab, nivolumabPD-1, LAG-3melanomaPhase 2-Phase 3714Bristol-Myers Squibb2018-04-11
RELATIVITY-060/NCT03662659Relatlimab, NivolumabPD-1, LAG-3Gastric cancer, esophagogastric junctionPhase 2274Bristol-Myers Squibb2018-10-16
NCT02060188Lpilimumab, nivolumabPD-1, LAG-3Microsatellite unstable colorectal cancer, microsatellite stable colorectal cancer, mismatch repair proficient colorectal cancer, mismatch repair deficient colorectal cancerPhase 2385Bristol-Myers Squibb2014-03-12